SCYNEXIS (SCYX) Expected to Post Quarterly Earnings on Wednesday

SCYNEXIS (NASDAQ:SCYX) is expected to issue its Q2 2026 results before the market opens on Wednesday, August 12th. Analysts expect the company to post earnings of ($0.5067) per share and revenue of $0.08 million for the quarter. Individuals may visit the the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Tuesday, August 11, 2026 at 4:00 PM ET.

SCYNEXIS (NASDAQ:SCYX) last issued its earnings results on Monday, May 11th. The company reported ($0.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.32). SCYNEXIS had a negative return on equity of 57.16% and a negative net margin of 41.79%. On average, analysts expect SCYNEXIS to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

SCYNEXIS Stock Performance

Shares of NASDAQ:SCYX opened at $5.40 on Wednesday. The firm’s 50 day simple moving average is $4.38 and its 200-day simple moving average is $5.89. SCYNEXIS has a one year low of $3.53 and a one year high of $10.48. The firm has a market cap of $53.62 million, a PE ratio of -1.41 and a beta of 1.09.

Hedge Funds Weigh In On SCYNEXIS

Hedge funds and other institutional investors have recently modified their holdings of the business. Jane Street Group LLC bought a new position in shares of SCYNEXIS during the second quarter valued at approximately $27,000. Bridgeway Capital Management LLC raised its stake in SCYNEXIS by 4.2% in the second quarter. Bridgeway Capital Management LLC now owns 368,180 shares of the company’s stock worth $248,000 after buying an additional 14,689 shares in the last quarter. Geode Capital Management LLC lifted its holdings in SCYNEXIS by 7.1% during the fourth quarter. Geode Capital Management LLC now owns 449,223 shares of the company’s stock worth $284,000 after buying an additional 29,775 shares during the period. Vanguard Group Inc. boosted its position in SCYNEXIS by 6.4% during the 3rd quarter. Vanguard Group Inc. now owns 1,762,322 shares of the company’s stock valued at $1,357,000 after acquiring an additional 105,600 shares in the last quarter. Finally, Goldman Sachs Group Inc. bought a new stake in SCYNEXIS during the 4th quarter valued at $1,255,000. 54.37% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

SCYX has been the topic of several research analyst reports. Wall Street Zen cut SCYNEXIS from a “buy” rating to a “sell” rating in a research note on Saturday, May 16th. Weiss Ratings upgraded SCYNEXIS from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, July 24th. Finally, Brookline Capital Markets reissued a “buy” rating on shares of SCYNEXIS in a research report on Friday. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $24.00.

SCYNEXIS Company Profile

SCYNEXIS, Inc is a late‐stage biopharmaceutical company focused on developing and commercializing novel anti‐infective therapies. Headquartered in Jersey City, New Jersey, the company’s primary research and development efforts center on combating invasive and chronic fungal infections, an area of high unmet medical need. SCYNEXIS’s scientific platform is built around its proprietary triterpenoid class of antifungals, which are designed to address resistance and safety limitations associated with existing treatments.

The company’s lead product candidate, ibrexafungerp, represents the first oral glucan synthase inhibitor to reach clinical development.